AbbVie may be working with some of the same advisers who worked on Pfizer's so-far-failed play for AstraZeneca. But after three rejections from target Shire–the latest totaling about $46.5 billion–it's not about to make Pfizer's same mistakes.
written on 27.06.2014
With Shire takeover bid, AbbVie looks to succeed where Pfizer failed
